DOI:
10.1055/s-00000003
Aktuelle Ernährungsmedizin
LinksClose Window
References
Prado CM, Bekaii-Saab T, Doyle LA et al.
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.
Br J Cancer 2012;
106: 1583-1586
We do not assume any responsibility for the contents of the web pages of other providers.